Arrowhead

2 products tracked · names used in filings: Arrowhead, Arrowhead Pharmaceuticals, Inc., Arrowhead Pharmaceuticals Ireland Limited

Upcoming milestones

No upcoming milestones listed.

Recent milestones

Fri 19 Jun 2026🇪🇺 EU approval (EC decision)

Redemplo (plozasiran) approved in the EU

Marketing authorisation to Arrowhead Pharmaceuticals Ireland Limited; Orphan, Additional monitoring · source

Thu 23 Apr 2026🇪🇺 CHMP positive opinion

Redemplo (plozasiran): CHMP positive opinion

Arrowhead Pharmaceuticals Ireland Limited; Orphan, Additional monitoring · source

Tue 18 Nov 2025🇺🇸 FDA approval

FDA approves Redemplo (plozasiran sodium), a new medicine

Arrowhead; NDA219947; New molecular entity; solution · source

Tue 18 Nov 2025🇺🇸 PDUFA datecompany-announced

plozasiran: PDUFA target action date (familial chylomicronemia syndrome)

Arrowhead Pharmaceuticals, Inc. (ARWR); plozasiran; NDA; status: set; "In addition, our commercial buildout is designed to make us launch ready on day one, should plozasiran receive regulatory approval on the November 18, 2025, PDUFA date,” said Christopher Anzalone, Ph.D., President and CEO at Arrowhead."; filed 2025-08-07 · source

Products

	Product	Status	Approved
🇪🇺	Redemplo plozasiran	Authorised	2026-06-19
🇺🇸	Redemplo plozasiran sodium	Approved	2025-11-18

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.